Breaking Medical News

October 26, 2000

Cutting-edge discoveries in hepatitis, liver transplants, and genetic liver disease to be revealed at National Medical Conference

DALLAS, TEXAS - The nation's leading biomedical researchers will present breakthrough therapies and technologies in liver disease October 29 through October 31 at the 51st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), the leading medical organization dedicated to the study of the liver and its diseases.

AASLD encourages the media to attend the more than 1,200 presentations covering liver-related diseases featuring previously-unpublished findings on such diverse topics as:

A pressroom will be available for media representatives in the Wyndham Anatole Hotel, Dallas, Texas, on Sunday, October 29 through Tuesday, October 31, daily from 8:00 a.m. to 6:00 p.m. at 214-761-2984.
For copies of abstracts, abstract summary highlights and press releases, to arrange for pre-conference researcher interviews, or to pre-register for onsite press credentials, contact Devon Ramirez at: 202-331-0175,

To view abstracts online go to:

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. Today, AASLD provides representation and education for nearly 2,400 liver researchers, physicians, and surgeons worldwide. Visit AASLD's website at:

K-M Communications

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to